The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The SUMF2 gene (UniProt accession Q8NBJ7) encodes an inactive C-alpha-formylglycine-generating enzyme 2, also known as pFGE (paralog of formylglycine-generating enzyme) or sulfatase-modifying factor 2 (schlotawa2020multiplesulfatasedeficiency pages 1-3, schlotawa2020multiplesulfatasedeficiency pages 3-5). This protein shares approximately 47% sequence identity with its paralog SUMF1, which encodes the active formylglycine-generating enzyme (FGE) (schlotawa2020multiplesulfatasedeficiency pages 1-3, schlotawa2020multiplesulfatasedeficiency pages 3-5). Both proteins belong to the evolutionarily conserved sulfatase-modifying factor family and contain the characteristic DUF323 domain, also known as the FGE fold (dickmanns2005crystalstructureof pages 1-2).
| Feature | SUMF2 / pFGE | SUMF1 / FGE comparison | Evidence |
|---|---|---|---|
| Human gene / protein identity | SUMF2 encodes pFGE (paralog of formylglycine-generating enzyme), also described as inactive C\u03b1-formylglycine-generating enzyme 2 and sulfatase-modifying factor 2 | SUMF1 encodes FGE, the active formylglycine-generating enzyme required for sulfatase activation | (schlotawa2020multiplesulfatasedeficiency pages 3-5, dickmanns2005crystalstructureof pages 1-2, ntenti2024thegeneticsbehind pages 3-5) |
| Evolutionary relationship | Shares ~47% homology/48% sequence identity with SUMF1/FGE and belongs to the same FGE/DUF323 protein family | FGE is the catalytically active paralog; both proteins are structurally closely related | (schlotawa2020multiplesulfatasedeficiency pages 3-5, dickmanns2005crystalstructureof pages 1-2) |
| Molecular size / precursor organization | Glycosylated human pFGE crystallized as a secretory-pathway protein; crystal model contained residues 28\u2013294, with C-terminal residues beyond 294 not resolved; N-glycosylation seen at Asn-191 | Human FGE is a 40 kDa, 374-residue glycoprotein with a cleavable ER signal peptide (residues 1\u201332), mature region 33\u2013374, and N-glycosylation at Asn-141 | (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 3-4, schlotawa2020multiplesulfatasedeficiency pages 1-3) |
| Overall structure / fold | Crystal structure solved at 1.86 \u00c5; adopts the characteristic FGE fold, a novel low-secondary-structure fold that became the structural paradigm for DUF323 proteins | FGE has a highly similar fold; structural similarity helped define why pFGE is inactive despite preserving substrate-binding architecture | (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 2-3, schlotawa2020multiplesulfatasedeficiency pages 5-8) |
| Subcellular localization | ER-resident protein in the early secretory pathway; functions where newly synthesized sulfatases are matured | FGE is also ER-resident and is the active sulfatase-modifying enzyme in the ER | (dickmanns2005crystalstructureof pages 1-2, cervino2026sulfatasemodifyingfactors pages 4-7, dierks2003multiplesulfatasedeficiency pages 1-2) |
| Enzymatic activity status | No formylglycine-generating activity detected; binds sulfatase-derived peptide substrates but is catalytically inactive | FGE is the sole enzyme responsible for generating C\u03b1-formylglycine (FGly) in mammalian sulfatases | (dickmanns2005crystalstructureof pages 1-2, schlotawa2020multiplesulfatasedeficiency pages 3-5, dierks2003multiplesulfatasedeficiency pages 1-2) |
| Substrate recognition | Binds sulfatase peptides bearing the FGE recognition motif; likely recognizes the same sulfatase maturation context as FGE | FGE recognizes the conserved sulfatase motif centered on CxPxR within the catalytic domain and converts the target cysteine to FGly | (dickmanns2005crystalstructureof pages 1-2, schlotawa2020multiplesulfatasedeficiency pages 3-5, dierks2003multiplesulfatasedeficiency pages 1-2) |
| Primary biochemical role | Functions as an inactive regulator/antagonist of sulfatase activation rather than as a catalyst; evidence suggests it can reduce effective sulfatase activation by counterbalancing FGE | FGE catalyzes the post-translational oxidation needed to activate all cellular sulfatases | (cervino2026sulfatasemodifyingfactors pages 4-7, schlotawa2020multiplesulfatasedeficiency pages 3-5, dierks2003multiplesulfatasedeficiency pages 1-2) |
| Key binding partners | Binds sulfatase substrates/peptides and likely interacts with SUMF1/FGE; structural analysis suggests capacity for heterodimerization with FGE; may also participate in ER quality-control interactions | FGE interacts with sulfatase substrates and ER quality-control/trafficking factors including PDI, ERp44, ERGIC-53, ERp57 | (dickmanns2005crystalstructureof pages 6-7, schlotawa2020multiplesulfatasedeficiency pages 3-5, schlotawa2020multiplesulfatasedeficiency pages 1-3) |
| Oligomeric behavior | Crystal asymmetric unit contains a homodimer; buried surface/contact geometry suggested possible biological significance and raised the possibility of FGE-pFGE heterodimers | FGE was proposed to form heterodimers with pFGE based on the close structural match | (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 6-7) |
| Calcium-binding features | Contains two buried calcium-binding sites that appear structure-stabilizing rather than catalytic | FGE likewise contains two calcium ions stabilizing the fold | (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 6-7, schlotawa2020multiplesulfatasedeficiency pages 5-8) |
| Disulfide-bond features | Conserved internal disulfide bond between Cys-156 and Cys-290 stabilizes the fold | FGE preserves the homologous stabilizing disulfide and also contains additional cysteines, including catalytically important active-site cysteines absent from pFGE functionally | (dickmanns2005crystalstructureof pages 6-7, schlotawa2020multiplesulfatasedeficiency pages 5-8) |
| Catalytic-site distinction from FGE | Retains a sulfatase-binding cleft but lacks the catalytic machinery that makes FGE active; major differences cluster near the putative reaction center | FGE has the active catalytic center that supports oxygen-dependent FGly generation | (dickmanns2005crystalstructureof pages 2-3, schlotawa2020multiplesulfatasedeficiency pages 5-8) |
| Domains / family annotations supported by literature | Member of the FGE/DUF323 family with the characteristic FGE fold; literature supports the same family/domain assignment as UniProt | Same family, catalytically active representative | (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 2-3) |
| Biological functions inferred/observed | Modulates global sulfatase activity, thereby affecting sulfated substrate turnover and signaling; proposed to regulate the balance of sulfatase activation in the ER | FGE is essential for activation of all sulfatases, influencing lysosomal degradation, steroid metabolism, extracellular matrix remodeling, and signaling through HSPG-editing sulfatases | (cervino2026sulfatasemodifyingfactors pages 4-7, schlotawa2020multiplesulfatasedeficiency pages 3-5, buono2010sulfataseactivitiestowards pages 1-2) |
| Pathways / downstream biology | Through regulation of sulfatases, pFGE is linked to glycosaminoglycan/heparan sulfate sulfation status, extracellular matrix remodeling, and growth factor pathways such as FGF/Wnt/BMP-related signaling; zebrafish work supports a role in developmental timing via altered HSPG sulfation | FGE positively enables the same sulfatase-dependent pathways by permitting sulfatase activation | (cervino2026sulfatasemodifyingfactors pages 4-7, ntenti2024thegeneticsbehind pages 3-5, buono2010sulfataseactivitiestowards pages 1-2) |
| Disease / translational relevance | Human direct disease causality is less established than for SUMF1, but altered SUMF2 expression has been reported in recent association studies and plasma proteomic analyses; mechanistically it is relevant because increased SUMF2 could inhibit SUMF1-enhanced sulfatase activity | SUMF1 mutations cause multiple sulfatase deficiency (MSD), a severe multisystem lysosomal disorder | (rouskas2025periodicdietaryrestriction pages 1-2, schlotawa2020multiplesulfatasedeficiency pages 5-8, ntenti2024thegeneticsbehind pages 3-5) |
Table: This table summarizes the core properties of human SUMF2/pFGE, including identity, localization, structure, activity, interactions, and biological roles, with side-by-side comparison to SUMF1/FGE where that clarifies function. It is useful as a compact evidence-based reference for functional annotation of SUMF2.
Despite its structural similarity to SUMF1/FGE, SUMF2/pFGE completely lacks formylglycine-generating activity (dickmanns2005crystalstructureof pages 1-2, schlotawa2020multiplesulfatasedeficiency pages 3-5). While it binds sulfatase-derived peptides bearing the FGE recognition motif (CxPxR), it cannot catalyze the post-translational conversion of cysteine to C-alpha-formylglycine (FGly) that is essential for sulfatase activation (dickmanns2005crystalstructureof pages 1-2, schlotawa2020multiplesulfatasedeficiency pages 3-5). This is in stark contrast to SUMF1/FGE, which is the sole enzyme responsible for generating FGly in all cellular sulfatases—a critical post-translational modification that converts an active-site cysteine into FGly, enabling sulfatases to hydrolyze sulfate esters (dierks2003multiplesulfatasedeficiency pages 1-2, buono2010sulfataseactivitiestowards pages 1-2).
Rather than functioning as a catalyst, SUMF2/pFGE serves as a negative regulator of sulfatase activity (cervino2026sulfatasemodifyingfactors pages 4-7, schlotawa2020multiplesulfatasedeficiency pages 3-5). Evidence suggests that pFGE antagonizes the enhancing effects of SUMF1 on sulfatases, effectively modulating the overall level of sulfatase activation in cells (rouskas2025periodicdietaryrestriction pages 1-2). Recent work in zebrafish demonstrates that SUMF2 and SUMF1 function as a complementary regulatory pair: SUMF1 promotes sulfatase activity while SUMF2 inhibits it, with the balance between the two determining net sulfatase function (cervino2026sulfatasemodifyingfactors pages 4-7). In zebrafish gastrulation, the ratio of sumf2 to sumf1 expression inverts at a critical developmental timepoint, shifting the balance from high to low sulfatase activity and triggering convergence and extension morphogenesis through altered heparan sulfate proteoglycan (HSPG) sulfation patterns (cervino2026sulfatasemodifyingfactors pages 4-7).
The precise mechanism by which SUMF2 antagonizes SUMF1 remains incompletely understood, but available evidence indicates that pFGE binds both sulfatase substrates and likely interacts with FGE itself, potentially competing for substrate access or forming inactive heterodimers (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 6-7, cervino2026sulfatasemodifyingfactors pages 4-7). Co-expression studies have shown that pFGE can compromise the ability of FGE to generate catalytically active sulfatases (dickmanns2005crystalstructureof pages 1-2).
SUMF2/pFGE recognizes the same conserved sulfatase recognition motif as SUMF1/FGE, which is centered on the sequence CxPxR within the sulfatase catalytic domain (schlotawa2020multiplesulfatasedeficiency pages 3-5, dierks2003multiplesulfatasedeficiency pages 1-2). This motif is part of the larger sulfatase signature I sequence (C-STACG-P-STA-R) that is evolutionarily conserved across all sulfatases (schlotawa2020multiplesulfatasedeficiency pages 3-5). While SUMF2 binds peptides containing this motif, it does not perform the oxidation reaction that FGE catalyzes (dickmanns2005crystalstructureof pages 1-2). The preserved binding capability without catalytic function allows SUMF2 to act as a competitive inhibitor or modulator of SUMF1 activity toward newly synthesized sulfatases in the endoplasmic reticulum (cervino2026sulfatasemodifyingfactors pages 4-7).
SUMF2/pFGE is localized to the endoplasmic reticulum (ER), where it functions as an ER-resident protein (dickmanns2005crystalstructureof pages 1-2, cervino2026sulfatasemodifyingfactors pages 4-7, dierks2003multiplesulfatasedeficiency pages 1-2). This localization is maintained through ER retention mechanisms, including canonical and non-canonical retention signals (schlotawa2020multiplesulfatasedeficiency pages 1-3, schlotawa2020multiplesulfatasedeficiency pages 3-5). The ER is the site where newly synthesized sulfatases undergo post-translational modification by SUMF1/FGE during or shortly after translocation into the ER lumen (dierks2003multiplesulfatasedeficiency pages 1-2). Co-localization of SUMF2 with SUMF1 in the ER enables SUMF2 to regulate sulfatase activation at the critical site of FGly generation (dickmanns2005crystalstructureof pages 1-2, cervino2026sulfatasemodifyingfactors pages 4-7). The protein may also interact with ER quality control machinery, potentially including ERp44, which is involved in retaining ER-resident proteins (schlotawa2020multiplesulfatasedeficiency pages 1-3, schlotawa2020multiplesulfatasedeficiency pages 3-5).
The three-dimensional structure of human SUMF2/pFGE was determined by X-ray crystallography at 1.86 Å resolution, revealing a novel protein fold designated the "FGE fold" (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 2-3). This fold is characterized by an asymmetric partitioning of secondary structure elements with relatively low secondary structure content (13% α-helices, 20% β-sheets in FGE, with pFGE having similar proportions) (schlotawa2020multiplesulfatasedeficiency pages 5-8, dickmanns2005crystalstructureof pages 1-2). The structure serves as the structural paradigm for all proteins containing the DUF323 domain, a large family of prokaryotic and eukaryotic proteins with diverse functions (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 2-3).
The pFGE structure is stabilized by several key features:
Disulfide Bond: A conserved disulfide bridge connects Cys-156 in helix 4 to Cys-290 near the C-terminus, arresting a β-strand in close proximity to another β-strand to form part of the same β-sheet (dickmanns2005crystalstructureof pages 6-7). This disulfide bond is also conserved in FGE and plays a crucial structure-stabilizing role (dickmanns2005crystalstructureof pages 6-7).
Calcium Binding Sites: Two calcium ions are buried in the core of the protein and display low B-values, indicating their structure-stabilizing function (dickmanns2005crystalstructureof pages 6-7, dickmanns2005crystalstructureof pages 1-2, schlotawa2020multiplesulfatasedeficiency pages 5-8). The first calcium site is located in the center of a bipyramidal arrangement coordinated by Asn-194, Asp-208, and water molecules. The second site shows more irregular coordination involving multiple carbonyl groups (dickmanns2005crystalstructureof pages 6-7). These calcium-binding sites are conserved across the DUF323 family (dickmanns2005crystalstructureof pages 6-7).
Cis-Proline Residues: The structure contains two cis-prolines at positions 53 and 201, with the latter contributing to the sharp kink in the polypeptide chain necessary for calcium coordination (dickmanns2005crystalstructureof pages 3-4).
The pFGE structure contains a deep cleft on its surface that is thought to be involved in binding sulfatase polypeptides (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 6-7). Pro-120 in pFGE, which corresponds to Pro-182 in FGE (a residue shown by cross-linking to interact with substrate peptides), borders one end of this cleft (dickmanns2005crystalstructureof pages 6-7). However, critical differences distinguish the inactive pFGE from the active FGE near the putative reaction center (dickmanns2005crystalstructureof pages 2-3, dickmanns2005crystalstructureof pages 6-7). While pFGE retains the overall architecture for substrate binding, it lacks the specific catalytic machinery present in FGE, including the catalytically active cysteine residues that FGE uses for FGly generation (dickmanns2005crystalstructureof pages 6-7, schlotawa2020multiplesulfatasedeficiency pages 5-8). Recent studies have shown that FGE utilizes copper as a cofactor, with Cu(I) coordinated by two active-site cysteines enabling oxygen activation for the oxidation reaction (schlotawa2020multiplesulfatasedeficiency pages 5-8); pFGE lacks this functional catalytic center.
The asymmetric unit of the pFGE crystal contains a homodimer with a buried surface area of 2,559 Ų and an actual contact area of 1,437 Ų per monomer (dickmanns2005crystalstructureof pages 6-7). The relatively small interaction area and surface complementarity coefficient (0.59) suggest that dimer formation might be weak but could be enhanced upon substrate binding (dickmanns2005crystalstructureof pages 6-7). Importantly, the high structural similarity between pFGE and FGE suggests that these proteins could form heterodimers, which would provide a direct mechanism for SUMF2 to antagonize SUMF1 function (dickmanns2005crystalstructureof pages 6-7, dickmanns2005crystalstructureof pages 1-2).
SUMF2 influences a broad range of biological processes by modulating the activity of cellular sulfatases. Sulfatases in mammals comprise 17 enzymes that remove sulfate groups from diverse substrates including glycosaminoglycans (GAGs), sulfolipids, steroid hormones, and heparan sulfate proteoglycans (HSPGs) (schlotawa2020multiplesulfatasedeficiency pages 3-5, buono2010sulfataseactivitiestowards pages 1-2). The majority of sulfatases are localized to the lysosome, where they degrade sulfated GAGs and sulfatides, but others function in the ER, Golgi, or on the cell surface (schlotawa2020multiplesulfatasedeficiency pages 3-5). By regulating sulfatase activity, SUMF2 affects:
Lysosomal Degradation: Sulfatase activity is essential for the breakdown of GAGs (heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate) and sulfatides in lysosomes (schlotawa2020multiplesulfatasedeficiency pages 3-5, buono2010sulfataseactivitiestowards pages 1-2). Reduced sulfatase activity leads to accumulation of these substrates and lysosomal dysfunction (schlotawa2020multiplesulfatasedeficiency pages 5-8).
Extracellular Matrix Remodeling: Extracellular sulfatases SULF1 and SULF2 modify heparan sulfate proteoglycans in the extracellular matrix and on cell surfaces by removing 6-O-sulfate groups from glucosamine residues (ntenti2024thegeneticsbehind pages 3-5, buono2010sulfataseactivitiestowards pages 1-2). This desulfation releases growth factors and cytokines sequestered by HSPGs, thereby activating downstream signaling (ntenti2024thegeneticsbehind pages 3-5).
Growth Factor and Morphogen Signaling: Through regulation of HSPG sulfation patterns, SUMF2 indirectly influences multiple growth factor and morphogen pathways including FGF (fibroblast growth factor), Wnt, BMP (bone morphogenetic protein), VEGF, PDGF, and TGF-β signaling (ntenti2024thegeneticsbehind pages 3-5, cervino2026sulfatasemodifyingfactors pages 4-7, buono2010sulfataseactivitiestowards pages 1-2). HSPGs serve as co-receptors for many of these signaling molecules, and sulfation patterns determine binding affinity and signaling output (ntenti2024thegeneticsbehind pages 3-5).
Recent work in zebrafish has revealed a novel role for SUMF2 in controlling the precise timing of developmental morphogenesis (cervino2026sulfatasemodifyingfactors pages 4-7). During zebrafish gastrulation, sumf1 is maternally expressed but its transcript levels drop sharply just before gastrulation onset, coinciding with a dramatic increase in sumf2 expression (cervino2026sulfatasemodifyingfactors pages 4-7). This inversion of the sumf1/sumf2 ratio predicts a reduction in net sulfatase activity and a consequent increase in substrate sulfation (cervino2026sulfatasemodifyingfactors pages 4-7).
Experimental manipulation of sumf1 and sumf2 expression confirms their opposing roles: overexpression of sumf1 delays convergence and extension (C&E) onset, while overexpression of sumf2 causes precocious C&E (cervino2026sulfatasemodifyingfactors pages 4-7). Conversely, loss of sumf1 accelerates C&E, while loss of sumf2 delays it (cervino2026sulfatasemodifyingfactors pages 4-7). The key effector of this regulation is the extracellular sulfatase Sulf1, which modifies HSPGs: altered levels of sulfated heparan sulfate shift C&E timing and suppress sumf1/sumf2 mutant phenotypes (cervino2026sulfatasemodifyingfactors pages 4-7). This demonstrates that SUMF2 controls developmental timing by reducing sulfatase activity, thereby increasing HSPG sulfation to promote or permit morphogenetic cell movements (cervino2026sulfatasemodifyingfactors pages 4-7).
Recent human studies have implicated altered SUMF2 expression or protein levels in several disease contexts:
Metabolic Health: In a study of dietary restriction, SUMF2 was among eight proteins showing the greatest magnitude of change in plasma during restriction of animal products, with increased SUMF2 levels associated with improved metabolic health profiles (rouskas2025periodicdietaryrestriction pages 1-2). The authors note that SUMF2 acts as an inhibitor of SUMF1's enhancing effects on sulfatases, suggesting that elevated SUMF2 may have inhibitory effects on sulfatase activity with downstream metabolic consequences (rouskas2025periodicdietaryrestriction pages 1-2).
Type 2 Diabetes and COPD: SUMF2 has been identified as a shared diagnostic marker for type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease (COPD), with validation showing altered expression in T-cell subpopulations (rouskas2025periodicdietaryrestriction pages 1-2). SUMF2 was downregulated in T cells in both disease contexts (rouskas2025periodicdietaryrestriction pages 1-2).
Sulfation and Airway Remodeling: In the context of COPD and airway remodeling, SUMF2 is discussed as part of the sulfatase activation pathway that regulates the sulfation status of glycosaminoglycans in the extracellular matrix, which influences growth factor signaling, inflammatory cell accumulation, and tissue repair (ntenti2024thegeneticsbehind pages 3-5, ntenti2024thegeneticsbehind pages 2-3).
Neurodegeneration: SUMF2 has been identified as a potential genetic modifier of Huntington's disease onset, with colocalization analyses suggesting that altered SUMF2 expression in brain tissue may influence disease progression (rouskas2025periodicdietaryrestriction pages 1-2).
These associations underscore the broad impact of SUMF2-mediated regulation of sulfatase activity on human health and disease.
SUMF2/pFGE binds sulfatase-derived peptides containing the FGE recognition motif, demonstrating its ability to recognize the same substrates as SUMF1/FGE (dickmanns2005crystalstructureof pages 1-2). This binding is likely mediated by the deep cleft identified in the crystal structure (dickmanns2005crystalstructureof pages 6-7). The preserved substrate-binding capability without catalytic activity suggests that SUMF2 may compete with SUMF1 for binding to newly synthesized sulfatases in the ER (dickmanns2005crystalstructureof pages 1-2, cervino2026sulfatasemodifyingfactors pages 4-7).
The high structural similarity between pFGE and FGE, combined with the observation that pFGE forms homodimers in the crystal, suggests that pFGE and FGE could form heterodimers (dickmanns2005crystalstructureof pages 6-7, dickmanns2005crystalstructureof pages 1-2). Such heterodimerization would provide a direct mechanism for SUMF2 to inhibit SUMF1 function, potentially by sequestering active FGE in inactive complexes or by altering its substrate access (dickmanns2005crystalstructureof pages 6-7). While this interaction has been proposed based on structural analysis, direct biochemical evidence for SUMF1-SUMF2 heterodimers remains to be fully established (cervino2026sulfatasemodifyingfactors pages 4-7, schlotawa2020multiplesulfatasedeficiency pages 3-5).
SUMF2/pFGE is retained in the ER through both canonical and non-canonical ER retention signals (schlotawa2020multiplesulfatasedeficiency pages 1-3, schlotawa2020multiplesulfatasedeficiency pages 3-5). The protein may interact with components of the ER quality control machinery, potentially including ERp44, a pH- and zinc-dependent chaperone that cycles between the ER and Golgi to retain ER-resident proteins (schlotawa2020multiplesulfatasedeficiency pages 3-5). For SUMF1/FGE, interactions with PDI (protein disulfide isomerase), ERp44, ERGIC-53, and ERp57 mediate ER retention, export, and retrieval (schlotawa2020multiplesulfatasedeficiency pages 3-5, schlotawa2020multiplesulfatasedeficiency pages 1-3); by analogy, SUMF2 may engage with similar machinery.
SUMF2/pFGE is co-expressed with SUMF1/FGE in many tissues, with equal pFGE/FGE ratios observed across different tissue types under basal conditions (dickmanns2005crystalstructureof pages 1-2). However, expression levels can vary dynamically. For example, during zebrafish development, sumf1 is maternally provided at high levels early on, while sumf2 expression is induced at gastrulation onset, inverting their relative abundance (cervino2026sulfatasemodifyingfactors pages 4-7). In mammalian systems, SUMF1 is ubiquitously expressed with highest levels in kidneys and pancreas (schlotawa2020multiplesulfatasedeficiency pages 3-5). While comprehensive tissue-specific expression data for SUMF2 is more limited, the functional studies in zebrafish and disease association studies in humans suggest that SUMF2 expression is dynamically regulated in response to developmental or physiological cues (cervino2026sulfatasemodifyingfactors pages 4-7, rouskas2025periodicdietaryrestriction pages 1-2).
SUMF2/pFGE belongs to the sulfatase-modifying factor family and is part of the larger DUF323 protein family, which comprises 164+ members across prokaryotes and eukaryotes (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 2-3). These proteins share the characteristic FGE fold but have diverged functionally, with roles ranging from antibiotic biosynthesis to transcriptional regulation (dickmanns2005crystalstructureof pages 1-2). The paralogous relationship between SUMF2 and SUMF1 appears to be a vertebrate innovation, with both genes found in higher eukaryotes (schlotawa2020multiplesulfatasedeficiency pages 1-3, schlotawa2020multiplesulfatasedeficiency pages 3-5). The 47% sequence identity between human SUMF2 and SUMF1 reflects substantial divergence, particularly in the catalytic site region, which accounts for the loss of enzymatic activity in SUMF2 (dickmanns2005crystalstructureof pages 1-2, dickmanns2005crystalstructureof pages 2-3).
SUMF2 (sulfatase modifying factor 2) encodes pFGE, an ER-resident, catalytically inactive paralog of the formylglycine-generating enzyme SUMF1/FGE. Unlike SUMF1, which activates all cellular sulfatases by converting a conserved cysteine to formylglycine, SUMF2 lacks enzymatic activity but retains the ability to bind sulfatase substrates. This enables SUMF2 to function as a negative regulator of sulfatase activity, antagonizing the effects of SUMF1 and fine-tuning the balance of sulfatase activation in the endoplasmic reticulum.
The crystal structure of SUMF2 at 1.86 Å resolution reveals the novel FGE fold stabilized by disulfide bonds and two calcium ions, with a substrate-binding cleft that preserves the architecture for recognizing sulfatase peptides despite lacking the catalytic machinery. SUMF2 forms homodimers and may heterodimerize with SUMF1 to exert its inhibitory effects.
By regulating sulfatase activity, SUMF2 influences a broad range of biological processes including lysosomal degradation of glycosaminoglycans, extracellular matrix remodeling, and heparan sulfate-dependent signaling through pathways such as FGF, Wnt, and BMP. Recent studies have revealed a critical role for SUMF2 in developmental timing, where dynamic shifts in the SUMF2/SUMF1 ratio control the onset of convergence and extension morphogenesis through altered HSPG sulfation patterns. In humans, altered SUMF2 expression has been associated with metabolic health, type 2 diabetes, COPD, and neurodegenerative disease, underscoring its importance in both normal physiology and pathology.
SUMF2 represents an elegant regulatory mechanism that evolved to fine-tune the activity of the sulfatase system—a critical pathway for substrate desulfation and signaling in metazoans—by providing an inactive competitor that modulates the availability and activity of the active enzyme SUMF1.
References
(schlotawa2020multiplesulfatasedeficiency pages 1-3): Lars Schlotawa, Laura A. Adang, Karthikeyan Radhakrishnan, and Rebecca C. Ahrens-Nicklas. Multiple sulfatase deficiency: a disease comprising mucopolysaccharidosis, sphingolipidosis, and more caused by a defect in posttranslational modification. International Journal of Molecular Sciences, 21:3448, May 2020. URL: https://doi.org/10.3390/ijms21103448, doi:10.3390/ijms21103448. This article has 59 citations.
(schlotawa2020multiplesulfatasedeficiency pages 3-5): Lars Schlotawa, Laura A. Adang, Karthikeyan Radhakrishnan, and Rebecca C. Ahrens-Nicklas. Multiple sulfatase deficiency: a disease comprising mucopolysaccharidosis, sphingolipidosis, and more caused by a defect in posttranslational modification. International Journal of Molecular Sciences, 21:3448, May 2020. URL: https://doi.org/10.3390/ijms21103448, doi:10.3390/ijms21103448. This article has 59 citations.
(dickmanns2005crystalstructureof pages 1-2): Achim Dickmanns, Bernhard Schmidt, Markus G. Rudolph, Malaiyalam Mariappan, Thomas Dierks, Kurt von Figura, and Ralf Ficner. Crystal structure of human pfge, the paralog of the cα-formylglycine-generating enzyme*. Journal of Biological Chemistry, 280:15180-15187, Apr 2005. URL: https://doi.org/10.1074/jbc.m414317200, doi:10.1074/jbc.m414317200. This article has 39 citations and is from a domain leading peer-reviewed journal.
(ntenti2024thegeneticsbehind pages 3-5): Charikleia Ntenti, Eleni Papakonstantinou, Liana Fidani, Daiana Stolz, and Antonis Goulas. The genetics behind sulfation: impact on airway remodeling. Journal of Personalized Medicine, 14:248, Feb 2024. URL: https://doi.org/10.3390/jpm14030248, doi:10.3390/jpm14030248. This article has 8 citations.
(dickmanns2005crystalstructureof pages 3-4): Achim Dickmanns, Bernhard Schmidt, Markus G. Rudolph, Malaiyalam Mariappan, Thomas Dierks, Kurt von Figura, and Ralf Ficner. Crystal structure of human pfge, the paralog of the cα-formylglycine-generating enzyme*. Journal of Biological Chemistry, 280:15180-15187, Apr 2005. URL: https://doi.org/10.1074/jbc.m414317200, doi:10.1074/jbc.m414317200. This article has 39 citations and is from a domain leading peer-reviewed journal.
(dickmanns2005crystalstructureof pages 2-3): Achim Dickmanns, Bernhard Schmidt, Markus G. Rudolph, Malaiyalam Mariappan, Thomas Dierks, Kurt von Figura, and Ralf Ficner. Crystal structure of human pfge, the paralog of the cα-formylglycine-generating enzyme*. Journal of Biological Chemistry, 280:15180-15187, Apr 2005. URL: https://doi.org/10.1074/jbc.m414317200, doi:10.1074/jbc.m414317200. This article has 39 citations and is from a domain leading peer-reviewed journal.
(schlotawa2020multiplesulfatasedeficiency pages 5-8): Lars Schlotawa, Laura A. Adang, Karthikeyan Radhakrishnan, and Rebecca C. Ahrens-Nicklas. Multiple sulfatase deficiency: a disease comprising mucopolysaccharidosis, sphingolipidosis, and more caused by a defect in posttranslational modification. International Journal of Molecular Sciences, 21:3448, May 2020. URL: https://doi.org/10.3390/ijms21103448, doi:10.3390/ijms21103448. This article has 59 citations.
(cervino2026sulfatasemodifyingfactors pages 4-7): Ailen Soledad Cervino, Amrita Basu, Ryan J. Weiss, Gursimran Kaur Bajwa, Rubén Marín Juez, Sandra Grimm, Cristian Coarfa, and Margot Kossmann Williams. Sulfatase modifying factors control the timing of zebrafish convergence and extension morphogenesis. bioRxiv, Oct 2026. URL: https://doi.org/10.1101/2025.10.09.681375, doi:10.1101/2025.10.09.681375. This article has 1 citations.
(dierks2003multiplesulfatasedeficiency pages 1-2): Thomas Dierks, Bernhard Schmidt, Ljudmila V. Borissenko, Jianhe Peng, Andrea Preusser, Malaiyalam Mariappan, and Kurt von Figura. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human cα-formylglycine generating enzyme. Cell, 113:435-444, May 2003. URL: https://doi.org/10.1016/s0092-8674(03)00347-7, doi:10.1016/s0092-8674(03)00347-7. This article has 484 citations and is from a highest quality peer-reviewed journal.
(dickmanns2005crystalstructureof pages 6-7): Achim Dickmanns, Bernhard Schmidt, Markus G. Rudolph, Malaiyalam Mariappan, Thomas Dierks, Kurt von Figura, and Ralf Ficner. Crystal structure of human pfge, the paralog of the cα-formylglycine-generating enzyme*. Journal of Biological Chemistry, 280:15180-15187, Apr 2005. URL: https://doi.org/10.1074/jbc.m414317200, doi:10.1074/jbc.m414317200. This article has 39 citations and is from a domain leading peer-reviewed journal.
(buono2010sulfataseactivitiestowards pages 1-2): M. Buono and Maria Pia Cosma. Sulfatase activities towards the regulation of cell metabolism and signaling in mammals. Cellular and Molecular Life Sciences, 67:769-780, Mar 2010. URL: https://doi.org/10.1007/s00018-009-0203-3, doi:10.1007/s00018-009-0203-3. This article has 61 citations and is from a domain leading peer-reviewed journal.
(rouskas2025periodicdietaryrestriction pages 1-2): Konstantinos Rouskas, Ozvan Bocher, Alexandros Simistiras, Christina Emmanouil, Panagiotis Mantas, Anargyros Skoulakis, Young-Chan Park, Alexandros Dimopoulos, Stavros Glentis, Gabi Kastenmüller, Eleftheria Zeggini, and Antigone S. Dimas. Periodic dietary restriction of animal products induces metabolic reprogramming in humans with effects on cardiometabolic health. npj Metabolic Health and Disease, Apr 2025. URL: https://doi.org/10.1038/s44324-025-00057-2, doi:10.1038/s44324-025-00057-2. This article has 7 citations and is from a peer-reviewed journal.
(ntenti2024thegeneticsbehind pages 2-3): Charikleia Ntenti, Eleni Papakonstantinou, Liana Fidani, Daiana Stolz, and Antonis Goulas. The genetics behind sulfation: impact on airway remodeling. Journal of Personalized Medicine, 14:248, Feb 2024. URL: https://doi.org/10.3390/jpm14030248, doi:10.3390/jpm14030248. This article has 8 citations.